May 24, 2016
Recommended Topic Related To:

Intron A

"The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea an"...


Intron A



There is limited experience with overdosage. Postmarketing surveillance includes reports of patients receiving a single dose as great as 10 times the recommended dose. In general, the primary effects of an overdose are consistent with the effects seen with therapeutic doses of interferon alfa-2b. Hepatic enzyme abnormalities, renal failure, hemorrhage, and myocardial infarction have been reported with single administration overdoses and/or with longer durations of treatment than prescribed (see ADVERSE REACTIONS). Toxic effects after ingestion of interferon alfa-2b are not expected because interferons are poorly absorbed orally. Consultation with a poison center is recommended.

Treatment There is no specific antidote for interferon alfa-2b. Hemodialysis and peritoneal dialysis are not considered effective for treatment of overdose.


INTRON® A is contraindicated in patients with:

INTRON A and REBETOL® combination therapy is additionally contraindicated in:

  • Patients with hypersensitivity to ribavirin or any other component of the product
  • Women who are pregnant
  • Men whose female partners are pregnant
  • Patients with hemoglobinopathies (e.g., thalassemia major, sickle cell anemia)
  • Patients with creatinine clearance less than 50 mL/min. See REBETOL prescribing information for additional information.
This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 9/25/2014


Intron A - User Reviews

Intron A User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Intron A sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.